20030050.Her2HRneg
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.570
- INTERFERON_GAMMA_RESPONSE+0.570
- INTERFERON_ALPHA_RESPONSE+0.560
- IL6_JAK_STAT3_SIGNALING+0.470
- IL2_STAT5_SIGNALING+0.380
- INFLAMMATORY_RESPONSE+0.360
- TNFA_SIGNALING_VIA_NFKB+0.350
- COMPLEMENT+0.340
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.340
- KRAS_SIGNALING_UP+0.250
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.410
- MYC_TARGETS_V2-0.290
- WNT_BETA_CATENIN_SIGNALING-0.290
- UV_RESPONSE_DN-0.260
- ESTROGEN_RESPONSE_EARLY-0.240
- ANGIOGENESIS-0.220
- MITOTIC_SPINDLE-0.200
- MYC_TARGETS_V1-0.190
- APICAL_JUNCTION-0.180
- DNA_REPAIR-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | b4fd9abd-cb2a-4d1b-abb2-8e2796d009cc | — | — | 0.848 |
| 2 | 20110002.Her2HRneg | — | D | 0.840 |
| 3 | SRR8518167 | — | D | 0.838 |
| 4 | ERR2208892 | — | — | 0.831 |
| 5 | ERR2208965 | — | — | 0.827 |
| 6 | SRR8518312 | — | D | 0.823 |
| 7 | SAMN03290949 | — | — | 0.819 |
| 8 | aa5bae83-33a0-4b75-a52d-7ba53267f6d3 | — | — | 0.816 |
| 9 | TCGA-62-A46U-01A-11R-A24H-07 | — | cohortA1 | 0.814 |
| 10 | ff12dc45-d7ab-45ae-a049-2d20e3c546b6 | — | — | 0.811 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.570 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.570 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.560 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.470 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.380 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.360 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.350 | Inavolisib | — uncovered |
| COMPLEMENT | 0.340 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.340 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.250 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.240 | Cobimetinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.230 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.220 | Inavolisib | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| PEROXISOME | 0.190 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.170 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.170 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.160 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.150 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.130 | Inavolisib | — uncovered |